Patents by Inventor Samuel Goldman

Samuel Goldman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Humanized immunoglobulin reactive with B7 therewith
    Patent number: 6913747
    Abstract: The invention relates to humanized anti-B7-2 and anti-B7-1 antibodies, wherein each comprise a variable region of non-human origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.
    Type: Grant
    Filed: June 24, 1999
    Date of Patent: July 5, 2005
    Inventors: Man Sung Co, Maximiliano Vasquez, Beatriz Carreno, Abbie Cheryl Celniker, Mary Collins, Samuel Goldman, Gary S. Gray, Andrea Knight, Denise O'Hara, Bonita Rup, Geertruida M. Veldman
  • Antibodies to human IL-17F and other CTLA-8-related proteins
    Patent number: 6902735
    Abstract: Polynucleotides encoding human CTLA-8 (now known as IL-17F) and related proteins are disclosed. Human CTLA-8 and related proteins, including anti-human IL-17F antibodies, and methods for their production are also disclosed. Methods of treatment using human CTLA-8 proteins, rat CTLA-8 proteins and herpes CTLA-8 proteins are also provided.
    Type: Grant
    Filed: March 19, 2002
    Date of Patent: June 7, 2005
    Assignee: Genetics Institute, LLC
    Inventors: Kenneth Jacobs, Kerry Kelleher, McKeough Carlin, Samuel Goldman, Debra Pittman, Sha Mi, Steven Neben, Joanne Giannotti, Margaret M. Golden-Fleet
  • Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases
    Publication number: 20050079177
    Abstract: Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-? or TNF-?. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease.
    Type: Application
    Filed: September 11, 2003
    Publication date: April 14, 2005
    Applicant: Genetics Institute, LLC
    Inventors: John Leonard, Samuel Goldman, Richard O'Hara
  • Use of IL-12 antagonists in the treatment of rheumatoid arthritis
    Patent number: 6830751
    Abstract: Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-&ggr; or TNF-&agr;. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease.
    Type: Grant
    Filed: February 25, 2000
    Date of Patent: December 14, 2004
    Assignee: Genetics Institute, LLC
    Inventors: John Leonard, Samuel Goldman, Richard O'Hara, Jr.
  • Humanized immunoglobulin reactive with b7-2 and methods of treatment therewith
    Patent number: 6827934
    Abstract: The invention relates to a humanized anti-B7-2 antibody that comprises a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.
    Type: Grant
    Filed: July 27, 2000
    Date of Patent: December 7, 2004
    Assignee: Genetics Institute, LLC
    Inventors: Man Sung Co, Maximiliano Vasquez, Beatriz Carreno, Abbie Cheryl Celniker, Mary Collins, Samuel Goldman, Andrea Knight, Denise O'Hara, Bonita Rup, Geertruida M. Veldman, Gary S. Gray
  • Use of IL-12 antagonists in the treatment of conditions promoted by an increase in levels of IFN-y
    Patent number: 6706264
    Abstract: Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-&ggr; or TNF-&agr;. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease.
    Type: Grant
    Filed: February 25, 2000
    Date of Patent: March 16, 2004
    Assignee: Genetics Institute, LLC
    Inventors: John Leonard, Samuel Goldman, Richard O'Hara, Jr.
  • HUMANIZED IMMUNOGLOBULIN REACTIVE WITH B7-2 AND METHODS OF TREATMENT THEREWITH
    Publication number: 20020176855
    Abstract: The invention relates to a humanized anti-B7-2 antibody that comprises a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.
    Type: Application
    Filed: February 12, 1999
    Publication date: November 28, 2002
    Inventors: MAN SUNG CO, MAXIMILIANO VASQUEZ, BEATRIZ CARRENO, ABBIE CHERYL CELNIKER, MARY COLLINS, SAMUEL GOLDMAN, GARY S. GRAY, ANDREA KNIGHT, DENISE O'HARA, BONITA RUP, GEERTRUIDA M. VELDMAN
  • Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases
    Patent number: 6338848
    Abstract: Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-&ggr; or TNF-&agr;. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease.
    Type: Grant
    Filed: February 25, 2000
    Date of Patent: January 15, 2002
    Assignee: Genetics Institute, Inc.
    Inventors: John Leonard, Samuel Goldman, Richard O'Hara, Jr.
  • Polynucleotides encoding human CTLA-8 related proteins
    Patent number: 6074849
    Abstract: Polynucleotides encoding human CTLA-8 related proteins are disclosed. Human CTLA-8 proteins and methods for their production are also disclosed. Methods of treatment using human CTLA-8 proteins, rat CTLA-8 proteins and herpesvirus herpes CTLA-8 proteins are also provided.
    Type: Grant
    Filed: July 18, 1996
    Date of Patent: June 13, 2000
    Assignee: Genetics Institute, Inc.
    Inventors: Kenneth Jacobs, Kerry Kelleher, McKeough Carlin, Samuel Goldman, Debra Pittman, Sha Mi, Steven Neben, Joanne Giannotti, Margaret M. Golden-Fleet
  • Human CTLA-8 and uses of CTLA-8-related proteins
    Patent number: 6043344
    Abstract: Polynucleotides encoding human CTLA-8 and related proteins are disclosed. Human CTLA-8 proteins and methods for their production are also disclosed. Methods of treatment using human CTLA-8 proteins, rat CTLA-8 proteins and herpesvirus herpes CTLA-8 proteins are also provided.
    Type: Grant
    Filed: March 4, 1998
    Date of Patent: March 28, 2000
    Assignee: Genetics Institute, Inc.
    Inventors: Kenneth Jacobs, Kerry Kelleher, McKeough Carlin, Samuel Goldman, Debra Pittman, Sha Mi, Steven Neben, Joanne Giannotti, Margaret M. Golden-Fleet